Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients

ŠPINAROVÁ, Lenka, Jindřich ŠPINAR, Anna VAŠKŮ, Monika PÁVKOVÁ GOLDBERGOVÁ, Ondřej LUDKA, Josef TOMANDL a Jiří VÍTOVEC. Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients. Online. Experimental and Molecular Pathology. USA: The Human Press, 2008, roč. 84, č. 7, s. 250-255. ISSN 0014-4800. [citováno 2024-04-24]

Základní údaje

• Originální název: Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients
• Název česky: Genetika humorální a cytokinové aktivace u srdečního selhání a její význam pro stratifikaci rizika pacientů
• Autoři: ŠPINAROVÁ, Lenka (203 Česká republika, garant, domácí), Jindřich ŠPINAR (203 Česká republika, domácí), Anna VAŠKŮ (203 Česká republika, domácí), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Česká republika, domácí), Ondřej LUDKA (203 Česká republika, domácí), Josef TOMANDL (203 Česká republika, domácí) a Jiří VÍTOVEC (203 Česká republika, domácí)
• Vydání: Experimental and Molecular Pathology, USA, The Human Press, 2008, 0014-4800.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30201 Cardiac and Cardiovascular systems
• Stát vydavatele: Spojené státy
• Utajení: není předmětem státního či obchodního tajemství
• Impakt faktor: Impact factor: 1.930
• Kód RIV: RIV/00216224:14110/08:00026223
• Organizační jednotka: Lékařská fakulta
• UT WoS: 000257725700011
• Klíčová slova anglicky: Genetics;cytokines;chronic hear failure;stratification
• Štítky: chronic hear failure, cytokines, genetics, stratification
• Příznaky: Recenzováno

Anotace

Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients. Patients with ischemic heart disease (IHD) and previous MI showed a difference in the distribution of genotype G8002A for endothelin-1: allele G 0.718 and A 0.282 vs those without MI: allele G 0.882 and A 0.118, (p < 0.05). Patients with IHD and DM had allele G in 0.67 and A 0.33, while those without DM had allele G in 0.790 and A in 0.209 (p < 0.03). Patients with IHD and concomitant PAD had allele G in 0.718 and A in 0.282 vs those without PAD allele G in 0.882 and A in 0.118 (p < 0.0004). Patients with dilative cardiomyopathy (DCMP) showed no differences in genotype G8002A and presence of DM or PAD. It might be speculated that in the case of endothelin-1 and TNF alpha in CHF the genetic determination is not important, and plasma concentrations are influenced more by the disease severity. Ischemics with previous MI, concomitant DM or PAD showed more frequently allele A and less often allele G than those without these diseases. A genotype with allele A is associated with higher risk of concomitant diseases.

Anotace česky

Genetika humorální a cytokinové aktivace u srdečního selhání a její význam pro stratifikaci rizika pacientů. Patients with ischemic heart disease (IHD) and previous MI showed a difference in the distribution of genotype G8002A for endothelin-1: allele G 0.718 and A 0.282 vs those without MI: allele G 0.882 and A 0.118, (p < 0.05). Patients with IHD and DM had allele G in 0.67 and A 0.33, while those without DM had allele G in 0.790 and A in 0.209 (p < 0.03). Patients with IHD and concomitant PAD had allele G in 0.718 and A in 0.282 vs those without PAD allele G in 0.882 and A in 0.118 (p < 0.0004). Patients with dilative cardiomyopathy (DCMP) showed no differences in genotype G8002A and presence of DM or PAD. It might be speculated that in the case of endothelin-1 and TNF alpha in CHF the genetic determination is not important, and plasma concentrations are influenced more by the disease severity. Ischemics with previous MI, concomitant DM or PAD showed more frequently allele A and less often allele G than those without these diseases. A genotype with allele A is associated with higher risk of concomitant diseases.

Návaznosti

• MSM0021622402, záměr: Název: Časná diagnostika a léčba kardiovaskulárních chorob

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Časná diagnostika a léčba kardiovaskulárních chorob